Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes. Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is is a daily pill. Rybelsus TM was approved by the U.S. FDA in September 2019 as the first GLP-1 analog that does not need to be injected.

Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Apr 15;1221:123688. Epub 2023 Mar 22 PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment

Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?. JAMA. 2024 May 14;331(18):1519-1521. PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a comment you must login or register.

Sep 23, 2024 · Diabetes, high blood sugar, and insulin resistance are all associated with dementia. In Alzheimer’s disease, there is evidence for insulin resistance in the brain. Thus, there has been much interest in testing liraglutide and other GLP-1 analogs, such as exendin-4, semaglutide, and lixisenatide, as potential therapeutics for AD.

Mar 9, 2020 · Semaglutide; Paper Citations. Sa-Nguanmoo P, Tanajak P, Kerdphoo S, Jaiwongkam T, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.

Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis. J Neuroimmune Pharmacol . 2024 Jul 23;19(1):36.

Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults. BMJ Open. 2024 Jun 21;14(6):e081401. PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment

Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models. Biomed Pharmacother. 2024 Oct 13;180:117540. PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a comment you must login or register.

Nov 25, 2015 · This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials.

Xu R.Response to the letter titled "Analysis of semaglutide's effect on Alzheimer's disease risk". Alzheimers Dement. 2025 Jan 14; Epub 2025 Jan 14 PubMed.